Related Experiment Video
Updated: Jun 28, 2026
09:50
Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade
Published on: August 14, 2019
Two new isoflavanones from Erythrina costaricensis
Hitoshi Tanaka1, Hisanori Hattori, Tomoko Oh-Uchi
1Faculty of Pharmacy, Meijo University, Nagoya, Japan. hitoshi@ccmfs.meijo-u.ac.jp
Journal of Asian Natural Products Research
|November 13, 2008
Summary
Researchers discovered two novel isoflavanones from Erythrina costaricensis stems. These compounds, along with known isoflavonoids, were tested for antibacterial activity against methicillin-resistant Staphylococcus aureus.
Area of Science:
- Phytochemistry
- Natural Products Chemistry
- Medicinal Chemistry
Background:
- Erythrina species are a rich source of bioactive compounds.
- Isoflavanones are a class of flavonoids with diverse biological activities.
- The isolation of novel prenylated isoflavanones is of significant interest.
Purpose of the Study:
- To isolate and characterize new isoflavanones from Erythrina costaricensis.
- To evaluate the antibacterial potential of the isolated compounds against methicillin-resistant Staphylococcus aureus.
Main Methods:
- Phytochemical investigation of Erythrina costaricensis stems.
- Structure elucidation using spectroscopic techniques (NMR, MS).
- Antibacterial assays against methicillin-resistant Staphylococcus aureus (MRSA).
Main Results:
- Two new isoflavanones, characterized by a 2,2-dimethylpyran substituent and a prenyl analog, were identified.
- Two known isoflavonoids, cristacarpin and euchrenone b10, were also isolated.
- The antibacterial activities of the two new compounds against MRSA were evaluated.
Conclusions:
- Erythrina costaricensis is a source of rare, structurally unique isoflavanones.
- The novel compounds possess a prenyl analog moiety, contributing to their chemical distinctiveness.
- Further investigation into the antibacterial properties of these isoflavanones is warranted.
Related Concept Videos
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...